In the present review we discuss the complex interplay between BDNF signaling impairment, myelin disruption, and the progression of Alzheimer's disease, as well as the therapeutic potential of BDNF targeting in establishing a re-myelination approach in AD. This evidence concerns the gene BDNF and early-onset autosomal dominant Alzheimer disease.